India, April 16 -- Orthocell Ltd. (OCC.AX), a regenerative medicine company announced that it has approval for its Remplir nerve repair device to be used across the 51 United States Department of Defence and 170 Veterans Affairs hospital networks.
Orthocell will use its existing U.S. distributor network to reach military and veteran affairs surgeons in these hospital systems.
The recent clinical use of Remplir in 23 surgical procedures on injured soldiers in Ukraine, across both primary and secondary nerve repair applications, led to this expansion into the defence setting.
The firm noted that the Ukraine experience highlights key attributes of the device, including its portability, ease of use, and suitability for treating major traumat...